Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...
With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback